Mar 09

Novartis’ Phase III study of Jakavi in polycythemia vera meets principal endpoint

Novartis has declared that the Phase III study associated with Jakavi (ruxolitinib) has met its primary endpoint of maintaining haematocrit control (red blood cell volume) without the need for phlebotomy and reducing spleen size in patients along with polycythemia ver… (Source: Drug Development Technology)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Product sales here.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>